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BACKGROUND. The identification of patients with high-risk atherosclerotic plaques prior to
the manifestation of clinical events remains challenging. Recent findings question histology-
and imaging-based definitions of the “vulnerable plaque,” necessitating an improved
approach for predicting onset of symptoms.
METHODS. We performed a proteomics comparison of the vascular extracellular matrix and
associated molecules in human carotid endarterectomy specimens from 6 symptomatic
versus 6 asymptomatic patients to identify a protein signature for high-risk atherosclerotic
plaques. Proteomics data were integrated with gene expression profiling of 121 carotid
endarterectomies and an analysis of protein secretion by lipid-loaded human vascular
smooth muscle cells. Finally, epidemiological validation of candidate biomarkers was
performed in two community-based studies.
RESULTS. Proteomics and at least one of the other two approaches identified a molecular
signature of plaques from symptomatic patients that comprised matrix metalloproteinase 9,
chitinase 3-like-1, S100 calcium binding protein A8 (S100A8), S100A9, cathepsin B,
fibronectin, and galectin-3-binding protein. Biomarker candidates measured in 685 subjects
in the Bruneck study were associated with progression to advanced atherosclerosis and
incidence of cardiovascular disease over a 10-year follow-up period. A 4-biomarker
signature (matrix metalloproteinase 9, S100A8/S100A9, cathepsin D, and galectin-3-
binding protein) improved […]
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Introduction
Atherosclerosis is a chronic and progressive disease of the arterial 
wall and the main underlying cause of stroke, myocardial infarc-
tion (MI), and cardiac death (1, 2). The evolution of atherosclerotic 
plaques involves endothelial dysfunction, accumulation of lipids 
and inflammatory cells, as well as remodeling of the extracellular 
matrix (ECM). Previously, atherosclerotic plaques were defined 
by histological appearance. Plaques with thin fibrous caps and a 
large lipid pool were classified as “vulnerable lesions.” Lipid-poor 
plaques rich in ECM with thick fibrous caps were considered “sta-
ble.” Recent findings have challenged this “vulnerable plaque” con-
cept (3, 4): First, intravascular imaging revealed that only a small 
percentage of thin-capped plaques cause clinical events (4, 5). Sec-
ond, shifts in risk factor profiles (e.g., smoking cessation) and wide-
spread use of statins are associated with a change in histopathologi-
cal appearance of atherosclerotic lesions: “vulnerable plaques” with 
large lipid pools are far less common (3). Instead, superficial plaque 
erosions may trigger more cardiovascular events (3, 4).
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specimens and secretome analysis of lipid-loaded human vascular 
smooth muscle cells (SMCs). The proteomics data were integrated 
with plaque transcriptomic data from the Biobank of Karolinska 
Endarterectomies (BiKE) (11). The final selection of candidate 
biomarkers and a 4-biomarker signature derived from the indi-
vidual components was validated in the community-based Bru-
neck study, which is unique in its long-term follow-up and detailed 
monitoring of atherosclerosis manifestation and progression, and 
in a second independent cohort (Salzburg Atherosclerosis Preven-
tion program in subjects at High Individual Risk [SAPHIR] study).
Results
Proteomics of the ECM of carotid endarterectomies. We applied our 
published three-step extraction methodology (9, 10) to analyze 
ECM and ECM-associated proteins of carotid endarterectomy 
specimens previously analyzed by lipidomics (12). Six were from 
symptomatic and 6 from asymptomatic patients, with equal age 
Since histological appearance alone is insufficient to predict 
symptomatic disease, new approaches are needed to define the 
biological features of atherosclerotic lesions responsible for car-
diovascular syndromes and to test whether such features could 
be of clinical value in predicting events (4). Markers of systemic 
inflammation such as C-reactive protein (CRP) are elevated in 
subjects at risk for cardiovascular disease (CVD) but lack the spec-
ificity required for reliable differentiation between lesions from 
symptomatic and asymptomatic patients (6). Recent advances in 
elucidating molecular processes involved in plaque destabilization 
have highlighted the importance of the vascular ECM and its asso-
ciated proteins (7, 8). We have previously developed a proteomics 
methodology allowing a detailed analysis of the vascular ECM and 
associated proteins in the extracellular space (9, 10).
The aim of the present study was to identify a protein signa-
ture for symptomatic plaques by applying a tissue- and cell-based 
proteomics discovery approach involving carotid endarterectomy 
Figure 1. ECM proteomics of carotid endarterectomies. Volcano plots of differences in abundance in (A) the proteome of the NaCl fraction (n = 12) and (B) 
the proteome of the GuHCl fraction (n = 12) between symptomatic and asymptomatic patients. Colors represent FDR levels (red, FDR <1%; orange, FDR <5%; 
green, FDR <10%; blue, FDR ≥10%, by NSAF-PLGEM; FC, fold change), and the labeled dots are those that were significantly differentially expressed between 
the plaques from symptomatic and asymptomatic patients (FDR <10%). (C) Coexpression network in the NaCl fraction (n = 12) calculated from Pearson cor-
relations with edges defined at FDR <20% (Q values). The sizes of the nodes indicate the level of confidence for the differential expression between plaques 
from symptomatic and asymptomatic patients, and the colors represent different protein classifications (yellow, growth factors, cytokines, and regulatory 
factors; green, apolipoproteins; pink, collagens; orange, proteases/peptidases and inhibitors; blue, matricellular proteins and glycoproteins; white, other).
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each group, we found 110 ECM or ECM-
associated proteins in the GuHCl frac-
tion and 87 in the NaCl fraction, with an 
overlap of 51 (Supplemental Table 2).
When comparing carotid plaques 
from symptomatic and asymptomatic 
patients, we identified 18 proteins in 
the NaCl (Figure 1A) and 14 in the GuH-
Cl fraction (Figure 1B) that were differ-
entially expressed with an FDR <10%. 
Collagen triple helix repeat–containing 
protein 1 (CTHRC1) and apolipoprotein 
A1 (APOA1) proteins were identified in 
both fractions (Table 1). According to 
a disease association analysis, the 30 
differentially expressed proteins were 
enriched for several disease terms, 
including fibrosis, arterial occlusive 
diseases, vascular disease, and arte-
riosclerosis (FDR <0.001; WEB-based 
GEne SeT AnaLysis Toolkit; http://
www.webgestalt.org). Protein coex-
pression networks for the NaCl and the 
GuHCl fractions are shown in Figure 1C 
and Supplemental Figure 1, respective-
ly. Characterization of classical cellular 
markers and immunoblot confirma-
tion of differences for selected proteins 
are shown in Supplemental Figure 2. 
Plaques from symptomatic patients had 
less smooth muscle actin (SMA), but 
more osteopontin (SPP1), matrix metal-
loproteinase 9 (MMP9), and fibronec-
tin (FN1) (Supplemental Figure 3).
Transcriptomic profiling of carotid 
endarterectomies. In order to validate 
our proteomics findings, we interro-
gated the corresponding gene expres-
sion data for ECM and ECM-associated 
proteins in 121 carotid plaques of the 
BiKE cohort (from 84 symptomatic and 37 asymptomatic patients; 
Figure 2A) (11). With this approach, 14 transcripts (Figure 2B) were 
found to be differentially expressed between plaques from symp-
tomatic and asymptomatic patients, with an FDR <10% (Table 
2). Of the 30 differentially expressed proteins (ECM proteomics; 
Figure 1) and 14 differentially expressed genes (ECM transcrip-
tomics, Figure 2B), 5 were altered at both the transcript and the 
protein level (Figure 2C): cathepsin B (CTSB), chitinase 3-like-1 
(CHI3L1), matrix metalloproteinase 9 (MMP9), S100 calcium 
binding protein A8 (S100A8), and S100A9. All of these genes and 
corresponding proteins were positively correlated (Supplemental 
Figure 4) and upregulated in plaques from symptomatic versus 
asymptomatic patients.
Secretome analysis of lipid-loaded human SMCs. Recent findings 
using lineage tracing demonstrated that the contribution of SMCs 
to atherosclerotic plaques and to the regulation of proinflammatory 
responses has been greatly underestimated (13). Thus, we comple-
and sex distribution. To enhance classification accuracy, we select-
ed symptomatic patients who had ipsilateral carotid territory estab-
lished stroke documented by CT or MRI, while transient ischemic 
attack or amaurosis fugax relying on the patient self-report only 
were not considered. The patient characteristics are summarized 
in Supplemental Table 1 (supplemental material available online 
with this article; https://doi.org/10.1172/JCI86924DS1). Tissue 
decellularization was performed by 0.08% SDS to reduce the high-
ly abundant cellular proteins (9, 10). The two remaining fractions 
were analyzed by proteomics using a high mass accuracy tandem 
mass spectrometer: the initial salt (0.5 M NaCl) fraction, which 
contains newly synthesized and degraded extracellular proteins, 
and the final guanidine (4 M GuHCl) fraction, which contains 
predominantly ECM proteins and proteins tightly associated with 
the ECM in the vasculature (9, 10). Using a 95% peptide probabil-
ity, 99% protein probability, 10 ppm mass accuracy, a minimum 
of two peptides per protein and detection in at least 2 samples in 
Table 1. Proteins differentially expressed between symptomatic and asymptomatic plaques
Protein ID Fold change (log2) FDR Gene Protein name
NaCl fraction
S10A9_HUMAN 1.10 0.004 S100A9 Protein S100-A9
OSTP_HUMAN 1.38 0.005 SPP1 Osteopontin
S10A8_HUMAN 0.68 0.019 S100A8 Protein S100-A8
LG3BP_HUMAN 1.93 0.020 LGALS3BP Galectin-3-binding protein
APOA2_HUMAN –0.81 0.022 APOA2 Apolipoprotein AII 
CTHR1_HUMAN –1.45 0.035 CTHRC1 Collagen triple helix repeat containing 1 
TETN_HUMAN –0.64 0.036 CLEC3B Tetranectin
CO3A1_HUMAN –1.67 0.041 COL3A1 Collagen alpha-1 (III)
CH3L1_HUMAN 1.18 0.045 CHI3L1 Chitinase 3-like-1
TIMP2_HUMAN 2.11 0.045 TIMP2 Metalloproteinase inhibitor 2
FINC_HUMAN 0.59 0.052 FN1 Fibronectin
APOC3_HUMAN –0.55 0.063 APOC3 Apolipoprotein C-III
MMP9_HUMAN 1.24 0.064 MMP9 Matrix metallopeptidase 9
APOL1_HUMAN 1.21 0.073 APOL1 Apolipoprotein L1 
KAIN_HUMAN –1.27 0.074 SERPINA4 Kallistatin
APOA1_HUMAN 0.36 0.075 APOA1 Apolipoprotein A1 
APOD_HUMAN –0.61 0.084 APOD Apolipoprotein D 
TIMP1_HUMAN 0.88 0.099 TIMP1 Metalloproteinase inhibitor 1
GuHCl fraction
APOB_HUMAN 1.88 0.004 APOB Apolipoprotein B 
SAA4_HUMAN 1.72 0.007 SAA4 Serum amyloid A-4 protein
APOA1_HUMAN 0.65 0.010 APOA1 Apolipoprotein A1 
CATG_HUMAN –3.09 0.011 CTSG Cathepsin G 
TIMP3_HUMAN –1.39 0.016 TIMP3 Metalloproteinase inhibitor 3
SAMP_HUMAN –0.40 0.035 APCS Serum amyloid P component
SPP24_HUMAN –1.37 0.031 SPP2 Secreted phosphoprotein 24
ASPN_HUMAN –0.75 0.032 ASPN Asporin
CBPA3_HUMAN –2.32 0.034 CPA3 Mast cell carboxypeptidase A
FETUA_HUMAN 1.15 0.052 AHSG Alpha-2-HS-glycoprotein
CATB_HUMAN 0.91 0.060 CTSB Cathepsin B 
HPLN1_HUMAN –0.78 0.060 HAPLN1 Hyaluronan and proteoglycan link protein 1
CTHR1_HUMAN –1.91 0.074 CTHRC1 Collagen triple helix repeat containing 1
PCOC1_HUMAN –0.93 0.098 PCOLCE Procollagen C-endopeptidase enhancer
Fold change in plaques from symptomatic vs. asymptomatic patients; significance at FDR <10%.
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MMP9, FN1, and tenascin C (TNC) in the conditioned medium of 
lipid-loaded SMCs (Figure 3D). Furthermore, when human aortic 
explants were treated with recombinant MMP9 ex vivo, proteolytic 
cleavage of FN1 and TNC co-occurred with a release of LGALS3BP 
from the vascular ECM (Figure 3E).
Immunohistological staining in carotid plaques. Immunohis-
tological staining for the identified proteins (S100A8, S100A9, 
CHI3L1, MMP9, LGALS3BP) along with cell markers (CD68: mac-
rophage marker, CNN and SMA: SMC markers) was performed on 
consecutive sections. Representative images from normal artery 
and carotid plaques are shown in Figure 4A. S100A8 and S100A9 
localized in the macrophage-rich areas in plaques, as shown by the 
CD68 staining, and were largely absent in normal arteries. Stain-
ing for MMP9 was observed throughout the plaque and was also 
absent in the control. CHI3L1 and LGALS3BP were present in both 
the normal and diseased artery but stronger in plaques. The latter 
is consistent with the detection of LGALS3BP in SMC cultures.
mented our tissue-based proteomics approach by a proteomics 
analysis of protein secretion by vascular SMCs. Human vascular 
SMCs were converted to a foam-like atherosclerotic phenotype 
using lipid loading as previously reported (14). Proteomics analyses 
were then performed on the ECM deposited by the cell layer and the 
conditioned media (Supplemental Tables 3 and 4). Approximately 
50% of the ECM proteins identified in lipid-loaded SMCs were in 
common with those in human atherosclerotic plaques, highlighting 
the importance of SMCs to pathological ECM changes in the vessel 
wall (Figure 3A). Galectin-3-binding protein (LGALS3BP) secretion 
was markedly increased in the conditioned media of lipid-loaded 
SMCs (P = 0.005, Figure 3B and Supplemental Table 4) and was 
observed in early atherosclerotic lesions in the human ascending 
aorta (Figure 3C). LGALS3BP was also differentially expressed in 
plaques from symptomatic versus asymptomatic patients (Figure 
1A, FDR = 0.02); connected with MMP9 and FN1 in the protein 
coexpression network (Figure 1C); and showed co-detection with 
Figure 2. Comparison between protein and gene expression levels. (A) Schematic for detecting differentially expressed proteins that were also differen-
tially expressed at the mRNA transcript level. (B) Volcano plot of differences in expression between symptomatic and asymptomatic patients (n = 121) for 
corresponding ECM-associated genes (green, FDR <10%; blue, FDR ≥10%, by limma), and the labeled dots are those that were significantly differentially 
expressed between the plaques from symptomatic and asymptomatic patients (FDR <10%). (C) Box plots for the 5 molecules in common for protein abun-
dance (NSAF) and normalized gene expression (n = 12, proteomics; n = 121, transcriptomics; FDR <10%). The box plots are as follows: black line, median; 
box edges, 1st and 3rd quartiles; whiskers, furthest point within 1.5 times the interquartile range.
The Journal of Clinical Investigation C L I N I C A L  M E D I C I N E
1 5 5 0 jci.org   Volume 127   Number 4   April 2017
not advanced atherogenesis. Several of the identified markers of 
symptomatic plaques provide distinct and additive information. A 
final risk model, built by a forward stepwise selection procedure 
and allowing for all biomarkers, comprised CTSD (odds ratio [OR] 
[95% CI], 1.3 [1.0–1.6]), LGALS3BP (OR [95% CI], 1.5 [1.1–1.9]), 
MMP9 (OR [95% CI], 1.3 [1.0–1.6]), and calprotectin (OR [95% 
CI] 1.3 [1.0–1.7]) for the ultrasound end point (advanced athero-
genesis). In this model, CTSD could be exchanged by CHI3L1, 
both of which were highly correlated (r = 0.51). The 4-biomarker 
signature unraveled for advanced atherogenesis also performed 
well for incident CVD.
Additionally, in a series of patients with recently symptomatic 
carotid stenosis (n = 17), we measured plasma levels of MMP9 and 
calprotectin and found them to be 2.2 and 1.6 times higher (fold 
change of geometric means) than in individuals from the Bruneck 
study (free of CVD and carotid stenosis, n = 516) under adjustment 
for age and sex (P < 0.001 each).
Next, we strove for additional replication in an independent 
cohort — the SAPHIR study (baseline characteristics shown in 
Supplemental Table 8). We chose a case-cohort design and identi-
fied 58 cases of incident CVD during a median follow-up of 11.9 
(interquartile range, 10.3–13.2) years. Four of the 5 biomarkers 
measured in SAPHIR showed associations with incident CVD, 
while replication failed for one (CHI3L1; Supplemental Figure 6). 
As to the latter finding, it has to be considered that the SAPHIR 
cohort was 14.3 years younger on average, and composition of the 
CVD end point differed in Bruneck (stroke > MI) and SAPHIR (MI 
> stroke). This may be relevant for CHI3L1 because previous stud-
ies have reported an exclusive association with stroke (17).
In the Bruneck study, consideration of the 4-biomarker signa-
ture along with standard CVD risk factors improved the C-statistic 
for the risk of advanced atherosclerosis by 0.048 (P = 0.0038), sur-
passing the improvement that was gained considering its individ-
ual components separately (Supplemental Figure 7). Furthermore, 
Epidemiological validation in two community-based stud-
ies. Baseline characteristics of subjects in the Bruneck study are 
shown in Supplemental Table 5. Mean age was 66.1 years, and 
355 (51.8%) were female. During the 10-year follow-up 91 of the 
685 individuals experienced the composite CVD end point of MI, 
stroke, or vascular death. A total of 560 individuals had ultraso-
nographic follow-up, with 102 showing progression to advanced 
complicated stages of plaque development (advanced atherogen-
esis) and 371 developing new atherosclerotic plaques or exhibiting 
progression of non-stenotic plaques (early atherogenesis), includ-
ing 129 of 278 subjects without carotid atherosclerosis at baseline.
Our discovery approach identified the following final selec-
tion of candidate proteins as an overlap of ECM proteomics with 
either ECM transcriptomics or SMC secretome analysis: MMP9, 
CHI3L1, S100A8, S100A9, CTSB, FN1, and LGALS3BP (Supple-
mental Figure 5). In the Bruneck Study, baseline plasma levels of 
FN1 and cathepsin D (CTSD) were available as part of two bio-
marker panels measured by proximity extension assays (CVD I 
and Inflammation I Panel, Olink) (15). Both CTSD and CTSB are 
lysosomal cathepsins, and CTSD was used as a surrogate of CTSB 
due to their similar localization and high inter-correlation. Dimers 
of S100A8 and S100A9 form the inflammatory protein complex 
calprotectin. Calprotectin, CHI3L1, MMP9, and LGALS3BP were 
measured by ELISA.
Baseline levels of these candidate biomarkers showed signif-
icant associations with advanced atherogenesis (under adjust-
ment for age and sex), whereas no or weak associations existed 
for early atherogenesis (Figure 4B and Supplemental Tables 6 
and 7). Moreover, all these proteins emerged as predictive of CVD 
events during the 10-year follow-up (age- and sex-adjusted mod-
el). Most associations remained robust in multivariable models. 
In line with our previous analyses (16), the standard vascular risk 
factors of high LDL cholesterol, hypertension, and cumulative 
exposure to smoking (pack-years) significantly related to early but 
Table 2. Transcripts differentially expressed between symptomatic and asymptomatic plaques
Affymetrix probe ID Gene ID Uniprot ID Fold change (log2) Average expression P value FDR
221204_s_at CRTAC1 CRAC1_HUMAN 0.39 8.30 5.31E–04 0.07
213176_s_at LTBP4 LTBP4_HUMAN –0.45 6.47 9.87E–04 0.07
201645_at TNC TENA_HUMAN 0.46 10.08 1.62E–03 0.07
201438_at COL6A3 CO6A3_HUMAN 0.34 11.06 1.90E–03 0.07
212190_at SERPINE2 GDN_HUMAN 0.41 9.55 3.12E–03 0.07
203535_at S100A9 S10A9_HUMAN 0.50 10.00 3.60E–03 0.07
216866_s_at COL14A1 COEA1_HUMAN –0.27 4.88 3.78E–03 0.07
200838_at CTSB CATB_HUMAN 0.40 12.65 4.54E–03 0.07
203697_at FRZB SFRP3_HUMAN –0.52 10.80 4.74E–03 0.07
209395_at CHI3L1 CH3L1_HUMAN 0.72 10.24 4.90E–03 0.07
204442_x_at LTBP4 LTBP4_HUMAN –0.45 8.39 5.20E–03 0.07
209396_s_at CHI3L1 CH3L1_HUMAN 0.71 9.49 5.47E–03 0.07
205907_s_at OMD OMD_HUMAN –0.45 9.14 5.58E–03 0.07
213274_s_at CTSB CATB_HUMAN 0.47 11.06 5.91E–03 0.07
202637_s_at ICAM1 ICAM1_HUMAN 0.33 7.48 8.55E–03 0.09
203936_s_at MMP9 MMP9_HUMAN 0.70 12.00 8.91E–03 0.09
202917_s_at S100A8 S10A8_HUMAN 0.53 10.54 9.06E–03 0.09
Significance at FDR <10%.
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consideration of the 4-biomarker signature significantly improved 
CVD risk prediction in terms of discrimination and risk classifica-
tion (Supplemental Figure 8). Finally, the incremental predictive 
value of the same 4-biomarker panel was similar in the SAPHIR 
study (Supplemental Figure 8).
Discussion
To date it is still not possible to accurately identify patients with 
high-risk atherosclerotic plaques before the manifestation of clini-
cal events. Here, we used three different approaches to discover a 
molecular signature for plaque instability that does not rely on imag-
ing or histopathological parameters but can be measured in the cir-
culation: First, a novel proteomics methodology targeting the ECM 
and ECM-associated proteins was applied to 12 carotid endarterec-
tomy specimens (from symptomatic versus asymptomatic patients), 
and selected findings were confirmed by immunoblotting. Second, 
the proteomics findings were integrated with the corresponding 
ECM-associated transcriptomic profiles of 121 carotid endarter-
ectomies from the BiKE cohort (11). Third, an in-depth analysis of 
proteins secreted by lipid-loaded versus unstimulated human SMCs 
(secretome) was performed. Proteins were considered candidate 
biomarkers for plaque destabilization when detected by plaque pro-
teomics and at least one of the two other approaches. Epidemiolog-
ical validation of the candidate biomarkers was performed in two 
independent prospective studies — the Bruneck and SAPHIR stud-
ies — and a final 4-biomarker signature was identified that signifi-
cantly improved clinical risk prediction along with the information 
provided by standard CVD risk factors (Supplemental Figure 8).
Figure 3. Proteomics of the secretome from lipid-loaded human vascular SMCs. (A) Schematic for detecting differentially expressed ECM proteins that 
also showed differential secretion in lipid-loaded human vascular SMCs. (B) The proteomics analysis of the conditioned media (“secretome”) showed the 
LGALS3BP level to be significantly higher in the lipid-loaded versus control SMCs (n = 6, ***P = 0.005, paired t test). The box plot is as follows: black line, 
median; box edges, 1st and 3rd quartile; whiskers, furthest point within 1.5 times the interquartile range. (C) Immunofluorescence staining for LGALS3BP 
(red) in early atherosclerosis (human ascending aorta). Autofluorescence of elastin fibers (green). Scale bars: 200 μm. (D) Validation by immunoblot-
ting. Note the co-detection of MMP9, FN1, LGALS3BP, and TNC upon lipid loading. SMCs from two different donors. Gelatin zymography for MMP2 was 
used as loading control. (E) Human aortic explants were either incubated with 50 pM MMP9 or left untreated for 24 hours. The degradation of FN1, TNC, 
and LGALS3B was examined by immunoblotting. MMP9 induces degradation of FN1 and TNC but releases LGALS3BP from human aortic explants. Aortic 
explants were from 2 different donors. Arrows indicate fragmentation products.
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The vascular ECM is crucial for the structural organization and 
integrity of the artery wall (7, 8). The ECM provides a scaffold for 
attachment of molecules secreted by vascular cells, as well as for mol-
ecules entering from the circulation. In disease states, degradation 
and pathological remodeling of the ECM promotes plaque develop-
ment and progression by trapping circulating lipoproteins and growth 
factors, which exert biological activity and critically determine plaque 
stability. To our knowledge, the current study is the first comprehen-
sive proteomics analysis of the ECM in human atherosclerotic plaques, 
whereas previous studies have focused on the cellular proteome (18) 
or particular components of the ECM (proteoglycans) (19). Our study 
provides insights into the composition of advanced atherosclerotic 
lesions featured by high levels of MMP9, CHI3L1, S100A8-S100A9 
(calprotectin), lysosomal cathepsins (CTSB), FN1, and LGALS3BP. 
These ECM-associated proteins were elevated at the proteome lev-
el, but were also differentially expressed in the plaque transcriptome 
and/or in the secretome of lipid-loaded human vascular SMCs.
Based on our findings, these proteins are promising biomark-
ers of plaque instability: First, they are locally expressed in the 
atherosclerotic plaque (transcriptomics/proteomics), with SMCs 
being a potential source (secretome analysis). Second, they are 
elevated in the plaques of symptomatic patients and detectable 
in the circulation, indicating that they may get released from 
unstable lesions. We provide some evidence that plasma levels of 
these markers indeed reflect their abundance in plaques; this is 
supported by previous studies (20–22). Finally, in the prospective 
community-based Bruneck Study, all identified candidates pre-
dicted the development of advanced atherosclerosis in a unique 
person-based progression model of atherosclerosis. Moreover, 
strong associations were found with incident cardiovascular 
events over the 10-year follow-up period, a majority of which 
derived from plaque rupture and atherothrombosis in both the 
Bruneck and SAPHIR studies, and a 4-biomarker signature sig-
nificantly improved risk prediction.
Figure 4. Biomarker candidates in tissue and plasma. (A) Immunohistochemistry staining for LGALS3BP, S100A8/A9, CHI3L1, and MMP9 plus SMC (SMA, 
CNN1) and macrophage (CD68) markers. Scale bars: 500 μm. (B) Association between the biomarker candidates and atherosclerosis (n = 560) and CVD  
(n = 685) in the Bruneck study. Direction and strength of associations are coded by color and significance levels by size of frames. ORs are derived from 
logistic regression analysis, and hazard ratios from Cox models. ORs and hazard ratios are expressed for a 1-SD higher loge-transformed level of the given 
marker. Full details are presented in Supplemental Tables 6 and 7. Model 1 (M1) was adjusted for age (years) and sex. M2 was additionally controlled for 
standard vascular risk factors, including LDL cholesterol (mg/dl), HDL cholesterol (mg/dl), high-sensitivity CRP (mg/l), diabetes mellitus (0 vs. 1), hyper-
tension (0 vs. 1), smoking (pack-years), and body mass index (kg/m2). *Additionally adjusted for atherosclerosis score (mm).
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identified in a comparison of gene expression between stable and 
unstable segments of plaque obtained from the same patient (47).
CHI3L1 is a phylogenetically highly conserved protein asso-
ciated with various inflammatory disorders. The involvement of 
CHI3L1 in the pathogenesis of atherosclerosis and manifestation 
of CVD has recently been highlighted. Studies have shown that 
CHI3L1 levels are associated with both the presence and the extent 
of coronary artery disease and predict all-cause and cardiovascular 
mortality (48, 49). In case-control and community-based studies, 
elevated levels of CHI3L1 were associated with increased risk of 
stroke, but not MI (17, 50). In carotid endarterectomy specimens, 
CHI3L1 mRNA levels are higher in patients with symptomatic than 
those with asymptomatic disease (51). In contrast to CRP, a nonspe-
cific inflammatory marker produced in the liver, CHI3L1 is locally 
expressed by macrophages within inflamed arterial tissue (52).
FN1 is a classic marker of wound healing and is produced 
by activated macrophages, fibroblasts, and SMCs during tissue 
remodeling. FN1 binds cellular and ECM components (e.g., inte-
grins, TNC, etc.), thereby mediating cell adherence and plasticity. 
FN1 has been implicated in a number of diseases, including ather-
osclerosis (53). Interestingly, a recent experimental study showed 
that FN1 determines the inflammatory responsiveness of endothe-
lial cells to disturbed flow patterns, suggesting an important role of 
FN1 in the early stage of atherosclerosis (54). Nevertheless, studies 
investigating the association between circulating FN1 and coro-
nary artery disease have reported conflicting results (53).
Immunohistochemistry of the identified proteins (LGALS3BP, 
S100A8, S100A9, CHI3L1, MMP9) along with cell markers 
(CD68: macrophages; CNN and SMA: SMCs) showed localization 
in the plaque area, linking the plasma biomarkers to the underly-
ing pathology. Additional proteins were identified by one of the 
three discovery approaches but not confirmed by the others. Inter-
esting examples are extracellular molecules that have been previ-
ously implicated in plaque vulnerability, most notably osteopontin 
(SPP1), which was differentially expressed in our ECM proteomics 
analysis (FDR <0.01, Figure 1A) and for which a significant cor-
relation in 64 tissue-plasma sample pairs was observed in the 
Athero-Express cohort (55) (data not shown; r = 0.336, P = 0.007), 
providing further evidence that plasma levels are, at least to some 
extent, indicative of the protein abundance in atherosclerotic 
plaques. A previous proteomics study of human carotid samples, 
which unlike our study was not targeted toward the ECM, led to 
the identification of osteopontin as a prognostic marker for sec-
ondary manifestation of atherosclerosis (55).
The present study has notable strengths. First, we applied a 
proteomics technique optimized to study the ECM and proteins 
attached to the ECM. The comprehensive analysis of the ECM 
allows a detailed characterization of the composition and changes 
of the extracellular environment occurring during atherosclero-
sis progression and plaque destabilization. Thus far, proteomics 
studies have used whole tissue lysates (18, 55), and only one study 
restricted their analysis to proteoglycans of the ECM (19). Second, 
omics analyses were performed without a priori assumptions, 
thereby facilitating the potential discovery of biomarker candi-
dates. Third, we combined experimental and epidemiological 
research. The proteome signature identified was validated in two 
community-based studies.
MMP9, a zinc-dependent matrix protease typically produced 
by macrophages and vascular SMCs, is an established determi-
nant of ECM remodeling in atherosclerosis (23). MMP9 is elevat-
ed in advanced atherosclerotic lesions (24) and is positively asso-
ciated with neutrophil count and morphological characteristics of 
rupture-prone lesions (25). The protease colocalizes with neutro-
phils and macrophages at the shoulder region of atherosclerotic 
plaques and induces collagen breakdown in the fibrous cap, thus 
contributing to plaque vulnerability and rupture (25, 26). Circulat-
ing MMP9 has also been shown to predict clinical events such as 
stroke (27) and fatal CVD (28). While it is reassuring that the final 
selection includes established mediators of ECM degeneration 
like MMP9, omics analyses provide a more integrated assessment 
of the molecular signature in symptomatic atherosclerosis.
Calprotectin, a heterocomplex of the alarmins S100A8 and 
S100A9, is mainly produced by myeloid cells such as neutrophils 
and monocytes and is released in neutrophil extracellular traps 
(29). Calprotectin promotes migration of phagocytes, triggers 
endothelial activation, and regulates inflammatory processes by 
binding to Toll-like receptor 4 and the receptor for advanced gly-
cation end-products. Calprotectin shows increased gene expres-
sion in atherosclerotic carotid plaques from patients with recent 
symptoms (30). In human carotid endarterectomy specimens, 
levels of calprotectin correlate with features of plaque instability 
(31). Circulating calprotectin increases early in patients with acute 
MI and concentrations are highest at the site of coronary occlusion 
(32). Several studies have shown that calprotectin is associated 
with the severity of atherosclerosis (33, 34) and the risk of future 
cardiovascular events (35, 36).
LGALS3BP, also known as MAC-2 binding protein, is a mem-
ber of the macrophage scavenger receptor cysteine-rich domain 
superfamily (37). LGALS3BP has been implicated in the regula-
tion of innate immunity (38) and in the modulation of cell-cell and 
cell-matrix interactions (39). Its role in the vasculature is not well 
understood, but it has recently been shown to play a proinflamma-
tory role in human venous thrombosis via its binding to galectin 
3, enhancing leukocyte adhesion to the vessel wall and increas-
ing IL-6 expression (40). Notably, LGALS3BP is associated with 
carotid artery disease in patients with human immunodeficiency 
virus and hepatitis C virus infection (41). An in vitro study revealed 
the expression of LGALS3BP in proinflammatory M1 macrophag-
es (42). Therefore, LGALS3BP may be a marker of macrophage 
activation, but LGALS3BP is also produced by vascular SMCs. 
Its expression by SMCs after lipid loading and the deposition of 
LGALS3BP in the vascular ECM could affect leukocyte binding 
and activation in the vessel wall, with implications in atheroscle-
rosis progression as indicated by the association of circulating 
LGALS3BP with advanced atherosclerosis in the Bruneck Study.
Cathepsins are lysosomal proteases that are thought to play 
an important role in vascular ECM remodeling and atherogen-
esis (43). Cathepsins exert both intracellular and extracellular 
functions. They can degrade ECM components such as collagen 
and elastin and promote apoptotic processes. Several cathepsins, 
including cathepsins B and D, have been found to colocalize with 
macrophages in atherosclerotic lesions (44, 45), and cathepsin G 
has been found to play an important role in recruiting leukocytes to 
the arterial walls (46). Interestingly, cathepsin B has recently been 
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during an elective surgery (asymptomatic stenosis). The patients were 
age and sex matched (3 females and males in each group; Supplemen-
tal Table 1). The samples were immediately snap-frozen and kept in 
liquid nitrogen for further use.
Tissue extraction for proteomics. To remove plasma contaminants, 
carotid endarterectomy samples were partially thawed and weighed, 
and approximately 150 mg tissue per sample was placed in ice-cold 
PBS. The buffer was supplemented with 1% v/v proteinase inhibitor 
mixture (Sigma-Aldrich). In addition, 25 mM EDTA was added to 
ensure inhibition of metalloproteinase. While the tissue samples were 
immersed in the cold saline, they were diced with a scalpel into 8–10 
smaller pieces to facilitate the removal of plasma contaminants and 
the effective extraction of extracellular proteins as described below. 
The diced samples were first incubated in a 0.5 M NaCl, 10 mM Tris, 
pH 7.5 buffer supplemented with proteinase and phosphatase inhibi-
tor cocktails as above and 25 mM EDTA. The volume of the buffer 
was adjusted to 10:1 of the tissue weight (i.e., 100 mg in 1 ml). The 
samples were mildly vortexed for 4 hours at room temperature (RT). 
The NaCl extracts were then desalted with centrifugation using desalt-
ing columns (Zeba Spin, Pierce Biotechnology). After desalting, the 
extracts were mixed with 100% acetone (5:1 volume ratio) at –20°C 
for 16 hours. Proteins were precipitated with centrifugation (16,000 g 
for 45 minutes), and the pellets were vacuum dried and re-dissolved in 
deglycosylation buffer (see below). Subsequently, the aortic samples 
were incubated with 0.08% SDS (10:1 buffer volume to tissue weight), 
including proteinase and phosphatase inhibitor cocktails and 25 mm 
EDTA. The samples were mildly vortexed, to minimize mechanical 
disruption of the ECM, for 4 hours at RT. The SDS solution was then 
removed and stored frozen for later use. Finally, the samples were incu-
bated in a 4 M GuHCl, 50 mM sodium acetate pH 5.8 buffer (5:1 buf-
fer volume to tissue weight), plus proteinase and phosphatase inhibi-
tor cocktails and 25 mM EDTA. pH was adjusted to 5.8 to improve the 
extractability of proteoglycans (56). The samples were incubated for 
48 hours at RT and vortexed vigorously to enhance the mechanical 
disruption of ECM and ECM-associated proteins. After the denatur-
ing extraction, guanidine was removed by mixing the samples with 
100% ethanol (5:1 volume ratio) at –20ºC for 16 hours. Proteins were 
then precipitated with centrifugation (16,000 g for 45 minutes), and 
the pellets were washed with 90% ethanol, dried, and re-dissolved 
in deglycosylation buffer. Deglycosylation of the different extracts 
was achieved in a 150 mM NaCl, 50 mM sodium acetate pH 6.8 buf-
fer supplemented with proteinase inhibitors and 10 mM EDTA for 16 
hours at 37°C. The deglycosylation enzymes (0.05 U) were chondroi-
tinase ABC from Proteus vulgaris, keratanase from Bacteroides fragillis, 
and heparinase II from Flavobacterium heparinum. All enzymes were 
purchased from Sigma-Aldrich. After deglycosylation, the solutions 
were centrifuged (16,000 g for 10 minutes). Protein concentration 
was measured by UV absorbance at 280 nm using the Groves formula, 
[concentration (mg/ml) = (1.55 × A280) – 0.76 × A260], to account for 
nucleic acid interference (57).
Proteomics analysis of tissue extracts. The 0.5 M NaCl and 4 M 
GuHCl extracts were denatured and reduced in sample buffer 
containing 100 mM Tris, pH 6.8, 40% glycerol, 0.2% SDS, 2% 
β-mercaptoethanol, and 0.02% bromophenol blue and boiled at 96°C 
for 10 minutes (9). 35 μg of protein per sample was loaded and sepa-
rated on Bis-Tris discontinuous 4%–12% polyacrylamide gradient gels 
(NuPage, Invitrogen) alongside protein standards (prestained All Blue, 
A limitation of our study is that omics technologies can result 
in false positive findings. To overcome this drawback, we consid-
ered candidates only if they were detected by ECM proteomics and 
at least one of the two other discovery approaches. We acknowl-
edge that the list of identified proteins is not exhaustive for all 
proteins potentially involved in plaque destabilization. Moreover, 
although there is strong indirect evidence that plasma levels of the 
identified markers indeed reflect abundance in the plaque, direct 
support to this concept is still limited. Finally, the Bruneck and 
SAPHIR studies include only individuals of European descent, 
and therefore findings can only be generalized to this ethnicity.
In summary, we were able to unravel a proteome signature 
that is capable to differentiate between atherosclerotic plaques 
from symptomatic and asymptomatic patients and to predict the 
development of advanced atherosclerosis and cardiovascular 
events in the general population. Most proteomics studies to date 
have searched for biomarkers in plasma. Plasma, however, has the 
most complex proteome, exceeding the analytical capabilities of 
current mass spectrometers. Moreover, the origin of biomarkers 
in plasma can remain uncertain. Instead, we applied a proteomics 
approach targeted to the ECM of the diseased tissue and of the rel-
evant cell type. One of the remarkable observations in our study 
is that tissue-based proteomics focusing on extra- rather than 
intracellular proteins emerged as a highly efficient technique and 
yielded 30 differentially expressed proteins in a 6-to-6 compari-
son (after correction for multiple testing). In contrast, comparison 
of the transcriptome identified only 14 proteins in a much larger 
collection of 121 carotid plaques. The biomarker candidates were 
subsequently validated in two prospective community-based 
studies. In an exploratory plasma proteomics approach utilizing 
the read-out of the two multiplex assays (CVD and Inflammation 
Panel, Olink), less than 5% of the 131 proteins were significantly 
linked to advanced atherogenesis (data not shown), and most of 
the candidates were involved in coagulation or fibrinolysis (ath-
erothrombosis) or features of plaque instability (e.g., micro-cal-
cification). Thus, our tissue- and cell-based discovery approach 
resulted in a higher success rate of identifying biomarkers than a 
plasma proteomics screen of established and putative biomarkers 
of inflammation and CVD. Further exploration of the function of 
these candidate proteins in plaque destabilization is merited.
Our findings may well have potential clinical implications. 
First, the biomarker signature identified improves risk prediction 
of CVD (relying on plaque rupture/fissuring) and of the progres-
sion of advanced atherosclerosis. This concept may be further 
advanced to aid clinicians with risk stratifications of patients with 
carotid stenosis. Second, the biomarker signature (i) may be vali-
dated as a useful diagnostic tool in the acute management of CVD 
before markers of tissue damage (e.g., high sensitivity troponins) 
increase; and (ii) may inform clinicians about an atherothrombot-
ic origin of ischemic stroke.
Methods
Carotid endarterectomy samples. Atherosclerotic plaque samples were 
collected from 12 patients undergoing carotid endarterectomies (12). 
Six of those samples were obtained shortly after an acute cerebrovas-
cular event (symptomatic stenosis with ischemic stroke in the ipsilat-
eral carotid territory), and the remaining 6 samples were collected 
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at 96°C for 10 minutes. Samples were loaded, separated, silver stained, 
digested, and analyzed by LC-MS/MS as described above in Proteomics 
analysis of tissue extracts. The identification was performed with mass 
tolerance set at 10 ppm for the precursor ions and at 0.8 Da for fragment 
ions. The mass spectrometry proteomics data have been deposited to 
the ProteomeXchange Consortium via the PRIDE partner repository 
with the dataset identifier PXD005130 and DOI 10.6019/PXD005130.
Western blots. For immunoblotting, we followed standard proto-
cols (58). The 0.5 M NaCl and SDS extracts of the 12 endarterectomy 
samples were aliquoted and mixed with denaturing sample buffer 
and boiled at 96°C for 10 minutes. On separate 15-well 4%–12% poly-
acrylamide gels (NuPAGE, Invitrogen) for each extract, 30 μg protein 
was loaded and separated alongside protein standards. The separated 
proteins were then transferred onto a nitrocellulose membrane. Fol-
lowing transfer, the membranes were blocked with 5% fat-free milk 
powder in PBS and probed overnight at 4°C with primary antibodies in 
5% bovine serum albumin at a 1:1,500 dilution.
The primary antibodies used for 0.5 M NaCl extracts were FN1 (SC-
56391, clone SPM246, Santa Cruz Biotechnology Inc.), SPP1 (SC-20788, 
rabbit polyclonal, Santa Cruz Biotechnology Inc.), and fibromodulin 
(FMOD) (SC-25857, goat polyclonal, Santa Cruz Biotechnology Inc.). 
Primary antibodies for integrin beta 1 (ITB1) (SC-73610, clone 102DF5, 
Santa Cruz Biotechnology Inc.), CD68 (SC-70761, clone 3F103, Santa 
Cruz Biotechnology Inc.), CD31 (SC-31045, goat polyclonal, Santa Cruz 
Biotechnology Inc.), and SMA (A5691, clone 1A4, Sigma-Aldrich) were 
used on the SDS extracts. For human SMC experiments, the blots were 
also probed with antibodies to MMP9 (ab38898, rabbit polyclonal, 
Abcam), tenascin C (ab6393, clone BC-24, Abcam), fibronectin (SC-
56391, clone SPM246, Santa Cruz Biotechnology Inc.), and LGALS3BP 
(70R-6085, rabbit polyclonal, Fitzgerald).
The membranes were then treated in appropriate horseradish 
peroxidase–conjugated secondary antibodies at a 1:2,000 dilution. 
Enhanced ChemiLuminescence (ECL, GE Healthcare) was used for 
imaging, and the exposed films were developed on a Xograph proces-
sor. ImageJ software (V.1.4.3.67; NIH) was used for densitometry of 
each lane of the developed films.
MMP9 zymography. MMP9 activity of the 0.5 M NaCl extracts of 
the 12 carotid endarterectomy specimens was determined by SDS-
PAGE gelatin zymography. The extracts were mixed with non-reduc-
ing sample buffer and electrophoresed in SDS-PAGE gels containing 
0.1% gelatin. Gels were incubated in the presence of metalloprotein-
ase activating buffer (50 mM Tris, pH 7.4, and 200 mM NaCl with 
2.5% Triton X-100) at RT for 1 hour and subsequently in metallo-
proteinase activating buffer at 37°C overnight. The gels were stained 
with Coomassie blue. Proteolysis was detected as a clear band against 
a blue background. The activity of MMP9 was determined by densi-
tometry. A similar approach was used for conditioned media of SMCs. 
MMP2 was used as loading control.
MMP9 digestion. Human aortic explants were incubated with 50 
pM MMP9 (Calbiochem) or left untreated, for 24 hours at 37°C. The 
degradation of FN1, LGALS3BP, and TNC was examined by immu-
noblotting as described above in Western blots.
Gene expression in carotid endarterectomies. Patients undergoing 
surgery for symptomatic or asymptomatic, high-grade (>50% NAS-
CET) (62) carotid stenosis at the Department of Vascular Surgery, 
Karolinska University Hospital, were consecutively enrolled as part 
of the BiKE study and clinical data recorded on admission. Symptoms 
Precision Plus, Bio-Rad). Gels were stained using the PlusOne Silver 
staining Kit (GE Healthcare). Silver staining was used for band staining 
to avoid cross-contamination with fainter gel bands (58). All gel bands 
were excised in identical parallel positions across lanes, and no empty 
gel pieces were left behind. Subsequently, all gel bands were subjected 
to in-gel tryptic digestion using an Investigator ProGest (Genomic 
Solutions) robotic digestion system. Tryptic peptides were separated 
on a nanoflow LC system (ThermoFisher Scientific UltiMate 3000) 
and eluted with eluent A (2% acetonitrile, 0.1% formic acid in H2O) 
and B (90% acetonitrile, 0.1% formic acid in H2O) using a 70-minute 
gradient (10%–25% B in 35 minutes, 25%–40% B in 5 minutes, 90% B 
in 10 minutes, and 2% B in 20 minutes). The column (ThermoFisher 
Scientific PepMap C18, 25-cm length, 75-μm internal diameter, 3-μm 
particle size) was coupled to a nanospray source (Picoview). During 
the liquid chromatography–mass spectrometry (LC-MS) run, spectra 
were collected from a high-mass accuracy analyzer (LTQ Orbitrap XL, 
ThermoFisher Scientific) using full ion scan mode over the mass-to-
charge (m/z) range 450–1,600. Tandem MS (MS/MS) was performed 
on the top 6 ions in each MS scan using the data-dependent acquisition 
mode with dynamic exclusion enabled. MS/MS peaklists were gener-
ated by extract_msn.exe and matched to human database (UniProtKB 
version 2013_8, 88,378 protein entries; http://www.uniprot.org/) 
using Mascot (version 2.3.01, Matrix Science). Carboxyamidomethyl-
ation of cysteine was chosen as fixed modification, and oxidation of 
methionine, lysine, and proline was chosen as variable modifications. 
The variable modifications of lysine and proline were included due to 
the large quantity of collagens in the samples. The mass tolerance was 
set at 1.5 AMU for the precursor ions and at 1.0 AMU for fragment ions. 
Two missed cleavages were allowed. Scaffold (version 4.3.2, Proteome 
Software Inc.) was used to calculate the normalized spectral counts, 
and to validate peptide and protein identifications (59, 60). Peptide 
identifications were accepted if they could be established at greater 
than 95.0% probability as specified by the Peptide Prophet algorithm 
(59). Only tryptic peptides were included in the analysis. Protein iden-
tifications were accepted if they could be established at greater than 
95.0% probability (60) with at least two independent peptides and a 
mass accuracy of ≤10 ppm of the precursor ion. ECM proteins identi-
fied for the first time by proteomics in the vasculature as well as ECM 
proteins with low spectral counts were further examined to ensure the 
quality of the identified spectra. The mass spectrometry proteomics 
data have been deposited to the ProteomeXchange Consortium via 
the PRIDE partner repository with the dataset identifier PXD005130 
and DOI 10.6019/PXD005130.
Human vascular SMC culture and proteomics analysis. Human vascu-
lar SMCs were obtained from explants of human aortic tissue as previ-
ously described (61). SMCs from 6 different donors ranging in age from 
20 to 54 years, both male and female, were used. SMCs were cultured 
in M199 medium (Sigma-Aldrich) supplemented with 20% FBS (Sig-
ma-Aldrich), 2 mM l-glutamine (Gibco), 100 U/ml penicillin, and 100 
mg/ml streptomycin, and used between passages 4 and 14. Lipid-load-
ed SMCs were obtained as previously described (14). The cell layer was 
lysed using RIPA buffer (Cell Signaling Technology). The serum-free 
conditioned media were concentrated using an Amicon 3 kDa molec-
ular weight cut-off spin column (Millipore). 30 μg cell layer proteins 
or 10 μg secreted proteins per sample were denatured and reduced in 
sample buffer containing 100 mM Tris, pH 6.8, 40% glycerol, 0.2% 
SDS, 2% β-mercaptoethanol, and 0.02% bromophenol blue and boiled 
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nial follow-up examination, with full data available in 685 individuals 
and a 10-year follow-up period (years 2000–2010).
All risk factors were assessed by means of validated standard pro-
cedures described previously (65–69). In brief, body mass index was 
calculated as weight divided by height squared (kg/m2). Hypertension 
was defined as blood pressure ≥140/90 mmHg (mean of 3 independ-
ent readings obtained with a standard mercury sphygmomanometer 
after at least 10 minutes of rest) or the use of antihypertensive drugs. 
Lifetime smoking was assessed as pack-years. Diabetes was defined 
based on ADA criteria (70). Blood samples were drawn in 2000 after 
an overnight fast and 12 hours of abstinence from smoking, and labo-
ratory parameters were measured by standard assays.
The composite CVD end point was composed of ischemic stroke, 
MI, and vascular death. Ischemic stroke was classified according to 
the criteria of the National Survey of Stroke (71). MI was deemed con-
firmed when World Health Organization criteria for definite disease 
status were met. Vascular mortality included deaths from ischemic 
stroke, MI, and rupture of aortic aneurysms and sudden cardiac deaths 
(72). Ascertainment of events did not rely on hospital discharge codes 
or the patient’s self-report but on a review of medical records provided 
by the general practitioners, death certificates, and Bruneck Hospital 
files, as well as the extensive clinical and laboratory examinations per-
formed as part of the study protocols. Major advantages of the Bruneck 
Study are that virtually all subjects living in the Bruneck area were 
referred to the local hospital and that the network existing between the 
local hospital and the general practitioners allowed retrieval of practi-
cally all medical information on persons living in the area.
At each study visit, participants underwent bilateral carotid 
duplex sonography using a 10-MHz transducer and a 5-MHz Doppler 
(16, 62, 64). All subjects were examined in supine position. The scan-
ning protocol involved 4 segments of the right and left carotid artery: 
proximal common carotid artery (15–30 mm proximal to the carotid 
bulb), distal common carotid artery (<15 mm proximal to the carot-
id bulb), proximal internal carotid artery (carotid bulb and initial 10 
mm of the vessel), distal internal carotid artery (>10 mm above the 
flow divider) (Supplemental Figure 9). A plaque was defined as a focal 
structure encroaching into the arterial lumen with a widening of the 
vessel wall of at least 0.5 mm relative to surrounding segments. The 
extent of carotid atherosclerosis was quantified by a scoring system 
adding the maximum axial thickness of atherosclerotic plaques (in 
mm) on the near and far wall at each of the 8 vessel segments.
A person-based atherosclerosis progression model (16, 67) was 
developed and validated in the Bruneck study that allowed differen-
tiation between early and advanced stages in atherosclerosis devel-
opment: (a) Early atherogenesis subsumes the manifestation of new 
plaques and/or nonstenotic progression of existing plaques. Main 
characteristics are a slow and continuous plaque growth usually 
affecting more than one plaque simultaneously and accompanied by 
a compensatory or even overcompensatory enlargement of the vessel 
at the plaque site. The term “incipient atherosclerosis” was used for 
the development of first plaques in subjects free of atherosclerosis at 
baseline. (b) Advanced complicated atherogenesis was assumed when 
the relative increase in the maximum plaque diameter exceeded twice 
the measurement error for the method (internal carotid artery, 24.8%; 
common carotid artery, 17%) (16) and a lumen narrowing of at least 
40% was achieved. This process is characterized by a usually solitary 
prominent increase in plaque size and the absence of vascular remode-
of plaque instability were defined as transitory ischemic attack, minor 
stroke, and amaurosis fugax. Patients without qualifying symptoms 
within 6 months prior to surgery were categorized as asymptomat-
ic, and indication for carotid endarterectomy was based on results 
from the Asymptomatic Carotid Surgery Trial (63). Plaque classifica-
tion was based solely on patient’s symptoms. The BiKE study cohort 
demographics, details of sample processing, and full microarray and 
statistical analyses have been previously described (11, 64), and the 
microarray dataset is available from the NCBI’s Gene Expression 
Omnibus (GSE21545). Briefly, global gene expression profiles have 
been analyzed by Affymetrix HG-U133 plus 2.0 Genechip microarrays 
in 127 patients’ plaque tissues (n = 87 symptomatic and n = 40 asymp-
tomatic) and n = 10 non-atherosclerotic (normal) arteries.
Immunohistochemistry. For the carotid plaques, all immunohis-
tochemistry reagents were from Biocare Medical. Tissues were fixed 
for 48 hours in 4% Zn formaldehyde at RT and paraffin-embedded. 
Isotype rabbit and mouse IgG were used as negative controls. In brief, 
5-μm sections were deparaffinized in Tissue Clear (Histolab) and 
rehydrated in graded ethanol. For antigen retrieval, slides were sub-
jected to high-pressure boiling in DIVA buffer (pH 6.0). After block-
ing with Background Sniper, primary antibodies were diluted in Da 
Vinci Green solution, applied on slides and incubated at RT for 1 hour. 
For colocalizations, antibodies for cell-specific markers were used: 
anti-SMA (M0851, clone 1A4, Dako), CNN1 (calponin, ab110128, 
goat polyclonal, Abcam), CD68 (M0876, clone PG-M1, Dako). Other 
antibodies against candidate biomarker proteins used in the study 
were: anti-LGALS3BP (70R-6085, rabbit polyclonal, R&D Systems), 
CHI3L1 (human chitinase 3-like-1) (AF2599, goat polyclonal, R&D 
Systems), S100A8 (ab92331, clone RPR3554 rabbit, Abcam), S100A9 
(ab92507, clone EPR3555 rabbit, Abcam), and MMP9 (ab38898, rab-
bit polyclonal, Abcam). A double-stain probe-polymer system con-
taining alkaline phosphatase and horseradish peroxidase was applied, 
with subsequent detection using Warp Red and Vina Green. Slides 
were counterstained with Hematoxylin QS (Vector Laboratories), 
dehydrated, and mounted in Pertex (Histolab). Images were taken 
using an automated ScanScope slidescanner. Scale bars are included 
in the images as indicated in the Figure legends.
In human aortic explants, after rehydration, the 3-μm sections 
were unmasked using hot sodium citrate buffer. Sections were washed 
3 times with PBS-Tween (PBST) and incubated with primary antibodies 
of LGALS3BP (70R-6085, Fitzgerald) or species-matched isotopes over-
night at 4°C after blocking with 10% FBS in PBST for 1 hour. Following 3 
washes in PBST, 5 minutes each, sections were incubated for 1 hour at RT 
with the secondary antibody (Alexa Fluor 594, Life Technologies) in 10% 
FBS/PBST, according to the source of the primary antibody. Nuclei were 
visualized using DAPI (1:1,000 dilution) for 10 minutes. Then sections 
were mounted on VectaMount (Vector Laboratories). Sections were visu-
alized with a 20× CFI S Plan Fluor ELWD ADM objective using an invert-
ed Nikon NI-E microscope equipped with a Yokogawa CSU-X1 spinning 
disk confocal unit and an Andor iXon 3 EM-CCD camera. Images were 
acquired using NIS-elements 4.0 software.
Study populations for epidemiological validation. The Bruneck 
study is a prospective community-based survey on the epidemiology 
and pathogenesis of atherosclerosis that started in 1990 (16, 65–69). 
The study population was recruited as a sex- and age-stratified ran-
dom sample of all residents aged 40 to 79 living in Bruneck (n = 4,739), 
Northern Italy. The present analysis focuses on the second quinquen-
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the BiKE study described in Perisic et al. (11), and only those were used 
for transcriptomic differential expression analysis. The linear models 
for microarray data (limma) method was used to detect differential 
expression at the probe level, and a FDR threshold of 10% was applied 
(77). All correlation values, including the coexpression networks, are 
Pearson correlations with associated P values. For the coexpression 
networks, the associated P values were corrected for using Q values, 
and a 20% FDR threshold was applied. The protein correlations were 
calculated after applying the NSAF normalization.
In the Bruneck study, associations of baseline ECM protein levels 
with early and advanced stages of atherosclerosis progression were 
analyzed by means of unconditional logistic regression analysis. The 
main analyses were adjusted for age and sex. Multivariable models 
additionally controlled for standard vascular risk factors, baseline 
atherosclerosis, and high-sensitivity CRP level. This model should be 
viewed as conservative because it considered adjustment for systemic 
inflammation and atherosclerosis burden, and some of the proinflam-
matory risk factors may well impact plaque stability by our candidate 
proteins. A final signature of biomarkers was identified by a forward-
stepwise selection procedure applying standard inclusion and exclu-
sion criteria. Cox proportional hazard models with adjustment for age 
and sex or multivariable adjustment (plus vascular risk factors and 
high-sensitivity CRP level) were used to assess whether baseline ECM 
protein levels were associated with new-onset CVD (2000 to 2010). 
We detected no departure from the proportional hazards assumption 
by inspecting Schoenfeld residuals and checking the parallelity of log-
log survival plots. We analyzed the case-cohort data from the SAPHIR 
study using Cox proportional hazard models with Prentice weights 
and robust standard errors (78).
This study used distinct approaches to assess the incremental 
predictive value afforded by markers of plaque vulnerability. First, the 
improvement in risk discrimination resulting from adding markers of 
plaque vulnerability to a model containing the standard Framingham 
risk factors was quantified using the C-statistic (logistic regression 
analysis on advanced atherosclerosis) and Harrell’s C-index (Cox 
models on incident CVD). The C-index is suitable for time-to-event 
data and gives the probability that the model correctly predicts the 
order of failure of randomly selected pairs of individuals. A C-index-
/C-statistic of 1.0 indicates perfect prediction of the order of failure, 
whereas a value of 0.5 is achieved purely by chance. The 95% CIs for 
C-indices and their changes were derived from jackknife standard 
errors. Comparison of the C-statistic/C-index for models including 
and not including vulnerability biomarkers (individual components 
and the 4-biomarker signature) was performed according to the 
method of DeLong (79) and with the Stata procedure somersd. Sec-
ond, we evaluated whether the 4-biomarker signature helps correctly 
classify participants into categories of predicted CVD risk. Using the 
10-year risk categories <5%, 5% to <7.5%, and ≥7.5%, the categorical 
net reclassification improvement (NRI) (80) was calculated. Separate 
analyses focus on the continuous NRI, which does not depend on the 
choice of categories, but deems any change in predicted risk in the 
correct direction as appropriate. Finally, we calculated the integrated 
discrimination improvement (IDI), which integrates the NRI over all 
possible cut-offs of predicted risk and mathematically corresponds to 
the difference in discrimination slopes of the 2 models in comparison 
(81, 82). Statistical analyses were performed with SPSS 22.0 and Stata 
12.0 MP software packages. All reported P values are 2-sided.
ling, resulting in significant lumen compromise (Supplemental Figure 
10). From a mechanistic perspective, it refers to plaque destabilization 
and subsequent atherothrombosis (16). The two progression cate-
gories were highly reproducible (κ coefficients >0.8 [n = 100]). Risk 
profiles differ significantly between the two stages of carotid artery 
disease, with early atherosclerosis relying on standard risk factors and 
advanced atherosclerosis being mainly related to markers reflecting 
plaque vulnerability or enhanced prothrombotic activity (69).
The SAPHIR study is a prospective cohort study conducted in 
1,770 healthy unrelated subjects (663 females and 1,107 males aged 
39–67 years) who were recruited by health screening programs in 
large companies in and around the city of Salzburg, Austria (73). The 
cohort was first examined in the years 1999–2002, reexamined in 
2003–2008, and followed until September 2013. At baseline and dur-
ing the follow-up visit, all participants were subjected to a comprehen-
sive examination, including a detailed medical history and physical, 
instrumental, and laboratory investigations (73, 74). Definitions of 
clinical variables were the same as in the Bruneck study.
For the current analysis, we used a case-cohort design. Of the 
1,770 participants in the SAPHIR study, we first excluded 433 partic-
ipants because they had no plasma sample, had an acute infection at 
enrollment (defined as CRP >4 mg/dl), had a history of CVD at enroll-
ment, or were lost to follow-up. Among the remaining 1,337 partici-
pants, we selected all participants with incident primary CVD event 
(defined as MI, ischemic stroke, or vascular death), all participants 
with CVD other than stroke and MI, plus an age- and sex-matched 
subcohort of 151 participants. In total, there were 58 incident events of 
the primary CVD outcome (6 in the subcohort) and 82 incident cases 
of additional CVD outcomes (15 in the subcohort).
Plasma samples from patients with symptomatic carotid stenosis. 
Plasma samples were drawn from 17 consecutive patients with symp-
tomatic carotid stenosis. The mean age was 70.8 ± 9.0 years, and 
70.6% were male. Plasma levels of MMP9 and CALP were measured 
using ELISA (MMP9 from R&D Systems, DMP900; and S100A8/A9 
from BMA Biomedicals).
Biomarker measurements in plasma. In the Bruneck year 2000 eval-
uation and the SAPHIR study, the following proteins were measured 
by ELISA in plasma samples according to the manufacturers’ instruc-
tions: MMP9 from R&D Systems (DMP900); CHI3L1 from R&D Sys-
tems (DC3L10); LGALS3BP from R&D Systems (DGBP30); S100A8/
A9 from BMA Biomedicals. Additional plasma proteins were analyzed 
using proximity extension assays (CVD I and Inflammation I panels, 
Olink) as previously published (15).
Statistics. Proteomic differential expression was assessed using the 
normalized spectral abundance factor–power law global error model 
(NSAF-PLGEM) (75). NSAF was calculated for each protein detected. 
Spectral count values of 0 were replaced by an empirically derived frac-
tional value. The value was calculated by detaining the smallest value 
between 0 and 1 that provided the best fit to a normal distribution. The 
fit to a normal distribution was determined with a Shapiro-Wilk test. For 
proteomics of human vascular SMCs, the differential expression in the 9 
proteins in common was assessed by a 2-tailed, paired t test with a Bon-
ferroni correction, significance <5% family-wise error rate. The disease 
association enrichment was performed using WebGestalt with all iden-
tified proteins as background (76).
From the identified plaque ECM proteins, gene expression was 
available for 120 corresponding genes (a subset of 231 probes) from 
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human vascular SMCs. JW designed and ran the Bruneck cohort. 
SK performed the epidemiological analysis. MM was involved 
with the study design, secured funding, and wrote the majority 
of the manuscript.
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